Gilde Healthcare
en nl de
  • Portefeuille
  • Team
  • Nieuws
  • Over ons
  • Contact

Nieuws 2011

2018 2019 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Follow @GildeHealthcare

BG Medicine, Inc. Files 510(k) for a diagnostic test to predict heart attacks

28 december 2011 – WALTHAM, Mass., - BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel, biomarker-based diagnostics, announced today that it has filed a 510(k) Premarket Notification with the U.S. Food and Drug Administration (FDA) for regulatory clearance…

Gerelateerd aan: BG Medicine

Ablynx Initiates Phase I Study with ALX-0171 for the Treatment of Respiratory Syncytial Virus (RSV)

13 december 2011 – GHENT, Belgium - Ablynx [Euronext Brussels: ABLX] today announced that it has initiated a Phase I study in healthy volunteers with ALX-0171, the first Nanobody in clinical development to be delivered by inhalation. ALX-0171 is being developed for the treatment of respiratory syncytial…

Gerelateerd aan: Ablynx

Symphogen Presents Positive Rozrolimupab (SYM001) Phase 2 Trial Results in ITP at ASH

12 december 2011 – COPENHAGEN, Denmark - Symphogen today presented final Phase 2 data demonstrating that its recombinant polyclonal antibody drug candidate rozrolimupab exhibited a favorable safety profile and induced a rapid increase in blood platelets in patients with Immune Thrombocytopenia Purpura…

Gerelateerd aan: Symphogen

Ablynx and Merck Serono Select a Novel Nanobody Candidate, ALX-0761, for Pre-Clinical Development

10 december 2011 – GHENT, Belgium - Ablynx [Euronext Brussels: ABLX] and partner Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that they have advanced the Nanobody candidate, ALX-0761, into pre-clinical development for the treatment of autoimmune diseases. This is the first…

Gerelateerd aan: Ablynx

Acacia Pharma announces positive results from Phase IIa cancer cachexia study

6 december 2011 – Cambridge, UK – Acacia Pharma, a pharmaceutical company specialising in the development of drugs for cancer supportive care, announces positive results from its Phase IIa study of APD209 in cancer cachexia. APD209 comprises a new and patent protected use for an oral combination of…

Gerelateerd aan: Acacia Pharma

Inova Labs receives CE Mark Approval for the LifeChoice® Portable Oxygen Concentrator System

1 december 2011 – New Technology enables COPD patients to experience true portability while maintaining appropriate oxygen concentration levels during both day and night Austin, TX – Inova Labs, a privately held medical device company focused on developing innovative products for the Chronic Obstructive…

Gerelateerd aan: Inova Labs

Ablynx Reports Positive Phase 1 Data for ALX-0061 in Rheumatoid Arthritis

30 november 2011 – GHENT, Belgium - Ablynx [Euronext Brussels: ABLX] today announced positive Phase I data from the single ascending dose part of the Phase I/II study with ALX-0061, the anti-IL-6R Nanobody, in patients with rheumatoid arthritis (RA). Based on these positive interim data, Ablynx has…

Gerelateerd aan: Ablynx

Profibrix successfully concludes Phase II clinical trial with Fibrocaps in liver resection surgery

17 november 2011 – LEIDEN, The Netherlands & SEATTLE, WA, USA - ProFibrix B.V., a leader in the development of innovative products for hemostasis, announced that its multicenter Phase II clinical trial with Fibrocaps in liver resection surgery resulted in a highly statistically significant 50% reduction…

Gerelateerd aan: ProFibrix

AMT Receives Orphan Designation in the European Union for Hemophilia B Gene Therapy

16 november 2011 – Amsterdam, The Netherlands – Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the European Medicines Agency (EMA) has granted orphan designation for its gene therapy program for the treatment of hemophilia B. Orphan…

ProFibrix Phase II with FibrocapsTM Meets Primary Endpoint – On Track for Phase III in 2012

15 november 2011 – LEIDEN, The Netherlands & SEATTLE -  ProFibrix B.V., a leader in the development of innovative products for hemostasis, today announced that its multicenter Phase II clinical trial with Fibrocaps in liver resection surgery resulted in a highly statistically significant 50% reduction…

Gerelateerd aan: ProFibrix

Gilde Healthcare Partners recruits new partners and opens new office in the US

10 november 2011 – Utrecht, the Netherlands | Cambridge, USA – Gilde Healthcare Partners a €450 million ($600 million) venture and growth capital group based in Utrecht, Netherlands has announced the opening of its office in Cambridge, MA. The firm’s US investment activity is managed by Geoff Pardo…

ABLYNX and Merck Serono expand their partnership into osteoarthritis

9 november 2011 – GHENT, Belgium - Ablynx [Euronext Brussels: ABLX] today announced that it has further expanded its relationship with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, and entered into a third agreement to co-discover and co-develop Nanobodies® against two targets in osteoarthritis.…

Gerelateerd aan: Ablynx

Gilde Healthcare III makes first investment in Inova Labs

8 november 2011 – Utrecht, the Netherlands | Cambridge, USA – Gilde Healthcare Partners announced today its first investment via Gilde Healthcare III in Inova Labs (Austin, TX). Inova Labs, a privately held medical device company focused on developing innovative products for the Chronic Obstructive…

Gerelateerd aan: Inova Labs

Santaris Pharma A/S advances the first microRNA-targeted drug to Phase 2 to treat Hepatitis C

8 november 2011 – Santaris Pharma A/S writes medical history and advances miravirsen, the first microRNA-targeted drug to enter clinical trials, into Phase 2 to treat patients infected with Hepatitis C virus Santaris Pharma A/S Phase 2a data of miravirsen shows dose-dependent, prolonged viral reduction…

Gerelateerd aan: Santaris Pharma

Conatus Pharmaceuticals Appoints Dr. Gary Burgess as Senior Vice President and Chief Medical Officer

1 november 2011 – SAN DIEGO – Conatus Pharmaceuticals Inc. announced today the appointment of Gary Craig Burgess, M.B., Ch.B. MMed, as Senior Vice President and Chief Medical Officer effective immediately. In this newly created position, Dr. Burgess will oversee all of the company’s clinical development…

Gerelateerd aan: Conatus Pharmaceuticals

Pieris Receives EUR 6 million Grant to Novel Anticalin Therapeutic to Treat Anemia

19 oktober 2011 – Freising, Germany - In concert with the award of the EU FP7 Grant to the Pieris-led EUROCALIN Consortium that will enable initial clinical development of Pieris’ proprietary hepcidin antagonist program, the company announced today the positive strategic impact of the grant funding…

Gerelateerd aan: Pieris Pharmaceuticals Inc.

Agendia Announces Completion of Patient Recruitment for International MINDACT Study

18 oktober 2011 – BRUSSELS, IRVINE, California, and AMSTERDAM /PRNewswire/ -- The EORTC, BIG, and Agendia, a commercial-stage molecular cancer diagnostics company, today announced the completion of patient registration for the EORTC 10041/BIG3-04 MINDACT (Microarray In Node negative and 1-3 positive…

Gerelateerd aan: Agendia

Gilde gaat meer investeren in de zorg

13 oktober 2011 – Utrecht - Participatiemaatschappij Gilde Healthcare Partners heeft meer dan €50 miljoen opgehaald voor het Gilde Healthcare Services fonds. Het fonds investeert in gespecialiseerde klinieken, ouderenzorg, eerstelijnszorg, GGZ, preventie, laboratoria en andere zorgbedrijven. “Innovatieve,…

ProFibrix Completes Enrollment of Phase II Studies with Lead Hemostasis Product Fibrocaps™

15 september 2011 – LEIDEN, The Netherlands & SEATTLE --(BUSINESS WIRE)-- ProFibrix B.V., a leader in the development of innovative products for hemostasis, today announced that it has completed patient enrollment in its two (U.S. and Dutch) prospective, randomized, controlled, multi-center Phase II…

Gerelateerd aan: ProFibrix

ProFibrix Completes Enrollment of Phase II Study with Fibrocaps

14 september 2011 – LEIDEN, The Netherlands & SEATTLE - ProFibrix B.V., a leader in the development of innovative products for hemostasis, today announced that it has completed patient enrollment in its two (U.S. and Dutch) prospective, randomized, controlled, multi-center Phase II studies with lead…

Gerelateerd aan: ProFibrix

Ascendis Pharma reports positive Phase 2 results

14 september 2011 – Palo Alto, California and Copenhagen, Denmark – Ascendis Pharma, a privately held specialty pharmaceutical company, announced positive results of a Phase 2 clinical study of ACP-001 in growth hormone deficient adults.   The Phase 2 clinical study met all primary and secondary endpoints,…

Gerelateerd aan: Ascendis Pharma

Agendia - International St. Gallen Expert Panel Highlights Importance of Molecular Subtyping

10 augustus 2011 – Panel’s Recommendations Reinforce Clinical Value of Tests Such as BluePrint­­® IRVINE, CA and AMSTERDAM, THE NETHERLANDS – Agendia, a commercial-stage molecular cancer diagnostics company, today announced that the 12th St. Gallen International Breast Cancer Conference (2011) Expert…

Gerelateerd aan: Agendia

mtm laboratories acquired for EUR 190 million

19 juli 2011 – Utrecht, The Netherlands – Gilde Healthcare Partners, a transatlantic investor in Healthcare Technologies and Services, announces the sale of its portfolio company mtm laboratories to Roche (SIX: RO, ROG; OTCQX: RHHBY) for a total consideration of EUR 190 million. Under the terms…

Gerelateerd aan: mtm laboratories

Innate Pharma signs Global License Agreement with BMS, potential deal value up to $465 million

7 juli 2011 – Princeton, New Jersey, and Marseille, France - Bristol-Myers Squibb Company (NYSE: BMY) and Innate Pharma S.A. (Euronext Paris: FR0010331421, IPH) announced a global agreement for the development and commercialization of IPH2102, a novel antibody in Phase I development for the treatment…

Gerelateerd aan: Innate Pharma

Gilde Healthcare II invests in Prosonix Ltd. (Oxford, UK)

5 juli 2011 – UTRECHT, The Netherlands – Gilde Healthcare Partners today announced an investment in Prosonix Ltd. (Oxford, UK), a leader in the development of high value respiratory therapies enabled by its novel and proprietary particle engineering technology.  Alongside Gilde Healthcare Partners,…

Gerelateerd aan: Prosonix

Gilde Healthcare Partners invests in Moximed, Inc.

30 juni 2011 – Utrecht, The Netherlands – Gilde Healthcare Partners today announced an investment in Moximed® Inc  (Hayward, CA, US), a developer of minimally invasive, joint preserving solutions for patients with knee osteoarthritis.  Alongside Gilde Healthcare Partners, new investors Frazier Healthcare…

Gerelateerd aan: Moximed

BG Medicine, Inc. Names Stephen R. Miller Chief Commercial Officer

28 juni 2011 – WALTHAM, Mass. - (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a life sciences company focused on the discovery, development, and commercialization of novel, biomarker-based diagnostics, announced today the appointment of Stephen R. Miller to the newly created position of Chief…

Gerelateerd aan: BG Medicine

Symphogen Presents Preliminary Results from Phase 2 Clinical Trial with Rozrolimupab

10 juni 2011 – Copenhagen, Denmark – Symphogen announced today preliminary data from a phase 2 clinical trial with rozrolimupab (SYM001) in adult, RhD positive, non-splenectomized patients with Immune thrombocytopenia (ITP). The study showed rozrolimupab is well tolerated with no unexpected toxicities…

Gerelateerd aan: Symphogen

Agendia announces details of its planned IPO on NYSE Euronext Amsterdam

6 juni 2011 – Amsterdam, the Netherlands – Agendia, a commercial-stage molecular diagnostics company  with  operations  in  the  Netherlands  and  the  United  States,  today announces  details  of its  planned  initial  public  offering  (the  “IPO”  or  “Offering”)  and contemplated  admission…

Gerelateerd aan: Agendia

Ablynx successfully completes a phase II study and demonstrates clinical proof-of-concept (POC) in p

19 mei 2011 – GHENT, Belgium - Ablynx [Euronext Brussels: ABLX] announced top-line results from the recently completed POC Phase II clinical trial of ozoralizumab (ATN-103), an anti-TNF-alpha Nanobody licensed to Pfizer, in patients with active rheumatoid arthritis (RA). The study evaluated five…

Gerelateerd aan: Ablynx

Agendia announces colorectal cancer collaboration with Astrazeneca and The Netherlands

11 mei 2011 – AMSTERDAM, THE NETHERLANDS, and IRVINE, CA – Agendia, an innovative molecular cancer diagnostics company, announced that it has partnered with AstraZeneca and The Netherlands Cancer Institute (NKI) to accelerate the development of targeted therapies for colorectal cancer patients.…

Gerelateerd aan: Agendia

Profibrix Raises EUR 15 Million

3 mei 2011 – LEIDEN, THE NETHERLANDS and SEATTLE, US - ProFibrix B.V., a leader in the development of innovative products that help stop bleeding (hemostasis) after surgery, today announced the successful closing of a series B follow-on financing. In conjunction with the financing and to support…

Gerelateerd aan: ProFibrix

Symphogen names new Chief Scientific/Medical and Business Officers Senior Management Team Complete

15 april 2011 – Copenhagen, Denmark – Symphogen, a private biopharmaceutical company developing superior antibody therapeutics (monoclonal, monoclonal mixtures and polyclonal) to treat cancer, infectious and autoimmune diseases, announced today the completion of its senior management team with the…

Gerelateerd aan: Symphogen

Pieris signs major collaboration with Daiichi Sankyo

12 april 2011 – Freising, Germany – Pieris AG announced today the signature of a collaboration and license agreement with Daiichi Sankyo Company Limited (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568), under which Pieris will apply its proprietary Anticalin scaffold technology…

Gerelateerd aan: Pieris Pharmaceuticals Inc.

Conatus Pharmaceuticals completes the second closing of its Series B Private Placement Financing

12 april 2011 – SAN DIEGO – Conatus Pharmaceuticals Inc. announced an additional $7.5 million investment by MPM Capital of South San Francisco, CA. The Series B Preferred Stock financing is now closed with a total of $32.5 million of capital raised. The first closing was completed in early February,…

Gerelateerd aan: Conatus Pharmaceuticals

BG Medicine Named To Russell 3000 Investment Index

1 april 2011 – WALTHAM, Mass., (GLOBE NEWSWIRE) - BG Medicine, Inc. (Nasdaq:BGMD) today announced that it has been added to the Russell 3000® Index, which measures the performance of the 3,000 largest publicly-traded U.S. companies based on total market capitalization. The Russell 3000 Index is…

Gerelateerd aan: BG Medicine

Conatus Pharmaceuticals presents results from a Phase 2 clinical trial of CTS-1027 in HCV genotype 1

31 maart 2011 – SAN DIEGO – Conatus Pharmaceuticals Inc. announced today 24-week interim results from a clinical trial with CTS-1027 in combination with Peginterferon Alpha-2a (Pegasys®) and ribavirin (Copegus®) in a treatment experienced, hepatitis C virus (HCV) null-responder patient population.…

Gerelateerd aan: Conatus Pharmaceuticals

Acacia Pharma Closes $10 Million Investment Round

31 maart 2011 – Cambridge, UK – Acacia Pharma, a pharmaceutical company specialising in the development of drugs for cancer supportive care, announces it has successfully closed a funding round, raising a total of $10 million. New investor Lundbeckfond Ventures joins Gilde Healthcare in this Series…

Gerelateerd aan: Acacia Pharma

BG MEDICINE announces Research Agreement with Boston Scientific on Cardiovascular Biomarkers

30 maart 2011 – Waltham, MA — BG Medicine, Inc. today announced that it has entered into a research collaboration agreement with Boston Scientific Corporation, a leading medical device manufacturer, to study the role of galectin-3 as an aid in patient screening for cardiac-resynchronization therapy…

Gerelateerd aan: BG Medicine

Study of CINtec® PLUS in the management of Pap negative but HPV positive women published

28 maart 2011 – Paper in Gynecologic Oncology shows that p16/Ki-67 dual staining can pinpoint those women that need immediate follow-up Heidelberg, Germany - mtm laboratories announced the publication of study results showing that the CINtec® PLUS kit for dual staining of p16 and Ki-67 is an effective…

Gerelateerd aan: mtm laboratories

Chroma Therapeutics enters collaboration with Cell Therapeutics Inc

14 maart 2011 – Oxford, UK and Seattle, US – Chroma Therapeutics Ltd and Cell Therapeutics, Inc. (“CTI”) (NASDAQ and MTA: CTIC) announced that the companies have entered into a co-development and license agreement providing CTI with exclusive marketing and co-development rights to Chroma’s drug candidate…

Gerelateerd aan: Chroma Therapeutics

Conatus Pharmaceuticals Will Display Hcv Clinical Trial Data At The International Liver Congress

11 maart 2011 – SAN DIEGO – Conatus Pharmaceuticals Inc. today announced the acceptance of two poster presentations of Phase 2 clinical trial data of CTS-1027 for the treatment of hepatitis C virus-infected patients at the 46th annual meeting of the European Association for the Study of the Liver…

Gerelateerd aan: Conatus Pharmaceuticals

Profibrix initiates phase II with lead hemostasis product Fibrocaps in US and Europe

8 maart 2011 – Leiden, The Netherlands and Seattle, WA – ProFibrix B.V., a leader in the development of innovative products for hemostasis, announced that it has initiated a prospective, multi-center Phase II study with its lead product Fibrocaps at up to 20 sites, including major U.S. and Dutch…

Gerelateerd aan: ProFibrix

Pieris to Present Interim Data from the Phase I Clinical Trial of PRS-050 at Molecular Medicine

22 februari 2011 – Freising, Germany — Pieris AG announced today the upcoming presentation of new preclinical and interim Phase I clinical trial data for its PRS-050 Anticalin® program, currently under evaluation for the treatment of cancer. Dr. Laurent Audoly, Chief Scientific Officer of Pieris, will…

Gerelateerd aan: Pieris Pharmaceuticals Inc.

Conatus Pharmaceuticals Initiates Confirmatory Phase 2 Clinical Trial Of Cts-1027 For The Treatment

17 februari 2011 – SAN DIEGO — Conatus Pharmaceuticals Inc. announced today the treatment of the first patient in a multi-center Phase 2b clinical trial evaluating CTS-1027 in combination with Peginterferon Alfa-2a (Pegasys®) and ribavirin (Copegus®) in a treatment experienced, hepatitis C (HCV) null…

Gerelateerd aan: Conatus Pharmaceuticals

Acacia Pharma initiates Phase IIa clinical trial with APD421 for nausea & vomiting

16 februari 2011 – Cambridge, UK – Acacia Pharma, a pharmaceutical company specialising in the development of drugs for cancer supportive care, announces it has initiated a dose-escalating, Phase IIa proof-of-concept study of its product candidate APD421. APD421 is an intravenous formulation of a currently…

Gerelateerd aan: Acacia Pharma

BG Medicine Announces Issuance of United States Patent for Galectin-3 Testing in Heart Failure

16 februari 2011 – WALTHAM, MA - BG Medicine (NASDAQ: BGMD), a life sciences company focused on the discovery, development, and commercialization of novel diagnostics based on biomarkers, today announced the issuance of U.S. Patent No. 7,888,137, entitled "Method For Identifying a Subject at Risk of…

Gerelateerd aan: BG Medicine

BG Medicine exercises over-allotment option and closing of IPO

14 februari 2011 – WALTHAM, Mass. - BG Medicine (NASDAQ: BGMD) announced that the underwriters of its initial public offering have exercised in full their over-allotment option to purchase an additional 750,000 shares of BG Medicine’s common stock at $7.00 per share, less underwriting discounts and…

Gerelateerd aan: BG Medicine

Conatus Pharmaceuticals Raises $20 Million

14 februari 2011 – SAN DIEGO  – Conatus Pharmaceuticals Inc. announced the closing of a $20 million Series B Preferred Stock private placement financing. This financing was led by new investor, AgeChem Venture Fund of Montreal, Canada, and included participation by existing investors; Aberdare Ventures,…

Gerelateerd aan: Conatus Pharmaceuticals

Conatus Pharmaceuticals Completes $20 Million Series B Private Placement Financing

11 februari 2011 – SAN DIEGO – Conatus Pharmaceuticals Inc. today announced the closing of a $20 million Series B Preferred Stock private placement financing. This financing was led by new investor, AgeChem Venture Fund of Montreal, Canada, and included participation by existing investors; Aberdare…

Gerelateerd aan: Conatus Pharmaceuticals

Acacia Pharma Completes Phase I Clinical Trial In Xerostomia

7 februari 2011 – Cambridge, UK – Acacia Pharma, a pharmaceutical company specialising in the development of drugs for cancer supportive care, announces it has completed a Phase I clinical study of its product candidate APD515, an optimised oromucosal formulation of a currently marketed drug for the…

Gerelateerd aan: Acacia Pharma

BG Medicine Announces Pricing of Initial Public Offering at NASDAQ

4 februari 2011 – WALTHAM, Mass. - BG Medicine (NASDAQ: BGMD) today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price of $7.00 per share, before underwriting discounts and commissions. All shares are being sold by the Company. The shares are expected…

Gerelateerd aan: BG Medicine

AMT Receives a Third of €3.3M EU Grant for Clinical Development of Gene Therapy

1 februari 2011 – Amsterdam Molecular Therapeutics (AMT) will receive €1.1 million (about $1.5 million) of a €3.3 million (approximately $4.5 million) grant being awarded by the European Union 7th Framework Program (FP7) to the AIPGENE consortium, which is working to develop a gene therapy product…

BG Medicine Announces Nationwide Availability of Galectin-3 Testing Service through LabCorp

18 januari 2011 – WALTHAM, Mass. --(BUSINESS WIRE)-- BG Medicine announced today that Laboratory Corporation of America®Holdings (LabCorp®)now offers galectin-3 testing services using the BGM Galectin-3 test for heart failure. The BGMGalectin-3 test was cleared by the FDA in November 2010 as an aid…

Gerelateerd aan: BG Medicine

Takeda San Francisco and Pieris Sign Anticalin® Therapeutic Collaboration

10 januari 2011 – San Francisco, USA and Freising-Weihenstephan, Germany — Takeda San Francisco (TSF) and Pieris AG have signed a drug discovery partnership agreement under which Pieris will apply its Anticalin® scaffold technology to deliver protein therapeutic candidates to Takeda, both companies…

Gerelateerd aan: Pieris Pharmaceuticals Inc.

BG Medicine and Siemens Healthcare Diagnostics to Develop Galectin-3 Test

6 januari 2011 – Waltham, MA— BG Medicine, Inc. announced today that it has entered into an agreement with Siemens Healthcare Diagnostics Inc., a division of Siemens Healthcare, one of the world’s largest suppliers of clinical diagnostics to the healthcare industry, for the development and commercialization…

Gerelateerd aan: BG Medicine

Symphogen Raises EUR 100 Million, The Largest Private Round In European Biotech Ever

6 januari 2011 – UTRECHT, Netherlands – Symphogen, a private biopharmaceutical company developing superior antibody therapeutics (monoclonal, monoclonal mixtures and polyclonal) to treat cancer, infectious and autoimmune diseases, announced that it closed a €100 million placement of Preferred Stock…

Gerelateerd aan: Symphogen

Gilde Healthcare

Gilde Healthcare

Gilde Healthcare is een gespecialiseerde Europese investeringsmaatschappij met EUR 1 miljard onder beheer in twee aparte fondsstrategieën: venture & groeikapitaal en private equity. Gilde Healthcare's venture & groeikapitaalfonds participeert in medische technologie, digitale zorgtechnologie en nieuwe geneesmiddelen. De venture & groeibedrijven zijn gevestigd in Europa en Noord Amerika. Gilde Healthcare’s private equity fonds neemt deel in winstgevende Europese bedrijven met een primaire focus op de middenmarkt in Benelux en Duitstalige landen. Het private equity fonds is gericht op zorgverleners, toeleveranciers en producenten van medische producten en overige dienstverleners actief in de zorgsector.

Investeringsfilosofie

Gilde Healthcare investeert in snelgroeiende, innovatieve bedrijven die betere zorg tegen lagere kosten mogelijk maken.

  • Home
  • Portefeuille
  • Team
  • Nieuws
  • Over ons
  • Contact
  • Imprint
  • Privacy Policy